🔬 Biologics In Focus | May 2025 Edition is now live! This month, we’re proud to unveil a major innovation in biologics manufacturing: GSquad® Pro, our next-generation gene expression vector. The novel LHP-1 promoter features enhanced control and improved titer and supports the efficient production of complex biologics, including bispecific antibodies and fusion proteins. In addition to this breakthrough, we explore: ✔️ Advances in synthetic production-phase promoters ✔️ Strategies for immunogenicity risk mitigation ✔️ Roche’s latest move to expand U.S. biologics production ✔️ And a look ahead to our June webinar on early biologics development strategies Join over 118,000 subscribers staying informed on the science, strategy, and innovations shaping the future of biologics. 👉 Subscribe now and share with your network https://lnkd.in/e9GgYKfk #IntegratedBiologics #BiologicsInFocus #Biotechnology #ThePeoplePoweringBiologics
Cesar Robin
1d
Bravo for all teams! Hello Lonza Recruiting directors, Hope you are well and family. With labor shortage having excellent FDA ,and sterile production experiences ;I can help Lonza !!! If you are looking for a candidate above average with very interesting Pharma ,chemical and Medical devices ,Nuclear Medicine ,Sterile production for Injectable vial ,CFR FDA ,QC,QA and Certification and even i sales; Thank you to contact me if you are looking for candidates able to make a difference on daily basis. ABLE to speak E-F-D-I and others. Able to train on the job please. Looking forward your contact please. Sincerely Cesar Robin
Excellent work
Thanks for sharing, especially on the need for early immunogenicity assessment. Antibodies (and biologics in general) are potent and specific, but at the same type not easy to handle. Any change in the folding of these molecules (and the presence of repeated amino acid ppatterns) could trigger immunogenicity responses which may be harmful for patients. Anti-drug antibodies assays, in-vitro cytokines profile evaluation and T- and B-cell behavior, must be evaluated early during the manufacturing and formulation process, to speed-up late stage development and approval processes.
Dimor Elbers
4d
Great to see the launch of the new synthetic fusion promoter for protein expression. Increasing yield and strengthening stability are key in optimizing manufacturing processes of protein based therapeutics.
Cristina L.
5d
Congratulations to Lonza on the launch of GSquad® Pro and the LHP-1 promoter, which enhance expression and stability in GS-CHO systems for complex molecules. Without a doubt, these advances drive efficiency and safety in biomanufacturing.
Omar Ali
5d
Congrats! 🎉
Some great additions to the Lonza platform technologies
Zeyu Li
1d
Congrats! 🎉
Licensing expert @Lonza.If you are expressing a protein or antibody therapeutic or AAV gene therapy I can help. Please contact me and lets chat about getting your therapy to patients.
5dExciting things happening at Lonza that can help you accelerate your therapies to the market.